Company profile: MS-Omics
1.1 - Company Overview
Company description
- Provider of metabolomics and data analysis services for small to large studies, offering fee-for-service analyses to universities and companies in biotechnology, pharmacy, and food. Capabilities include microbiome metabolite measurement (with Clinical-Microbiomics for next-generation sequencing), clinical, cell and bacteria, nutritional, and animal metabolomics, leveraging advanced mass spectrometry.
Products and services
- Clinical Metabolomics: Multi-matrix service analyzing saliva, faeces, caecum, urine, and blood to improve clinical research outcomes and support development of personalized medicine for healthcare studies
- Metabolomics Analysis: Scalable, fee-for-service metabolomics for universities and companies in biotechnology, pharmacy, and food, supporting small to large studies through comprehensive analysis for academic and industrial research
- Microbiome Analysis: NGS-integrated techniques measuring metabolites in cell tissue, faeces, blood, and urine, delivered via collaboration with Clinical-Microbiomics to enrich microbiome studies with next-generation sequencing data
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MS-Omics
Caribou Biosciences
HQ: United States
Website
- Description: Provider of CRISPR genome-editing technologies and allogeneic CAR-T cell therapies for oncology. Offers chRDNA to enhance precision and reduce off-target effects; off-the-shelf CAR-T therapies for hematologic malignancies and autoimmune diseases; and candidates CB-010 (anti-CD19 for B cell non-Hodgkin lymphoma), CB-011 (anti-BCMA for multiple myeloma), and CB-012 (anti-CLL-1 for acute myeloid leukemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Caribou Biosciences company profile →
Pierian
HQ: United States
Website
- Description: Provider of genomic SaaS solutions, a CAP and CLIA accredited laboratory, and a shared knowledgebase to enable physicians in the laboratory and clinic to diagnose and treat cancer and other complex diseases. Offerings include the Clinical Genomics Workspace, a knowledgebase with over 350,000 inferencing rules, professional services, IVD partnerships, EMR/LIS/EDW integration, and wet lab workflow guidance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pierian company profile →
Codexis
HQ: United States
Website
- Description: Provider of enzyme discovery and RNA manufacturing solutions, offering the CodeEvolver platform to discover, develop, and enhance novel enzymes and proteins; ECO Synthesis technology for scaled enzymatic production of RNAi therapeutics; custom enzymes to improve small molecule pharmaceutical manufacturing; RNA ligase screening and optimization; and high-yield RNA manufacturing services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Codexis company profile →
Enevolv
HQ: United States
Website
- Description: Provider of engineered and licensed microorganisms (i.e., bacteria and yeast) that produce chemicals, enzymes, and small molecules, advancing cost-effective, sustainable bioengineering solutions to address growing demand in energy, food, and medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enevolv company profile →
ReadCoor
HQ: United States
Website
- Description: Provider of the first true spatial multi-omic platform (RC2) that simultaneously detects and reads sequences, serving a global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and facilitate the creation of new therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ReadCoor company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MS-Omics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MS-Omics
2.2 - Growth funds investing in similar companies to MS-Omics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MS-Omics
4.2 - Public trading comparable groups for MS-Omics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →